The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
CDK inhibitors
CDK inhibitors
Cyclin-dependent kinase (CDK) pathways are often dysregulated in AML. CDKs control cell-cycle progression and gene transcription. Inhibiting CDKs can lead to downregulation of cell survival genes which are regulated by MCL-1, MYC,and cyclin D1. CDK9 is one target of therapeutic agents in AML. CDK inhibitors such as alvocidib, dinaciclib, and TG02 are in clinical development.
|
|